Q'Apel Medical

Overview

Q'Apel Medical is a medical technology company headquartered in Fremont, California, specializing in neurovascular intervention devices. Established in 2015, the company has made significant strides in the development and commercialization of novel vascular access technology. With a total of $69.03 million raised over five funding rounds, Q'Apel focuses on improving clinical outcomes for patients undergoing neurovascular procedures. The company is spearheaded by CEO Jodie Fam.

Recent Developments

October 31, 2024: Q'Apel Medical appointed Jay Hallinan as Chief Commercial Officer. With extensive experience from previous roles in Stryker and Medtronic, Hallinan is expected to enhance the company's commercial strategy and drive growth within the neurovascular market.
October 7, 2024: Route 92 Medical filed a patent infringement lawsuit against Q'Apel Medical, claiming infringement on multiple U.S. patents related to neurovascular devices.
May 9, 2024: The company completed a Series E funding round of $17.13 million, bringing its total funding to $69.03 million. RC Capital participated as one of the key investors in this round.
Armadillo Radial Access Platform: Q'Apel launched the Armadillo system, expanding its SelectFlex™ family of neurovascular access systems. This product supports a growing trend towards radial artery access in vascular procedures.
Expansion to New Facilities: Earlier, Q'Apel announced the relocation to a 35,000 square foot headquarters to accommodate increased manufacturing demands and support its expanding operations.

Attribute	Information
Founding Date	2015
Headquarters	Fremont, California, USA
Founders	Not publicly listed
Revenue	Estimated between $5-10 million annually
Profits	Not disclosed
Key Investors	RC Capital (among others)
Industry	Neurovascular Medical Devices
Number of Employees	Estimated at 111

Early History

Q'Apel Medical was founded in 2015 with the vision of addressing the unmet needs in neurovascular intervention technology. Recognizing the complexity of delivering effective treatments for stroke and vascular-related conditions, the company focused on designing access technologies that enable more precise interventions. The company’s name is inspired by the Qu'Appelle River, symbolizing its mission to navigate complex challenges in medical technology.

Company Profile and Achievements

Q'Apel Medical designs devices that enhance the trackability and support in navigating the neurovascular system. Among its flagship products are the Walrus Balloon Guide Catheter (BGC) and the Wahoo Control™ Catheter. These products are employed in over 185 hospital systems across the United States, showcasing Q'Apel's influence in the neurovascular arena.

Product Launches: The introduction of the Armadillo Radial Access System signifies Q'Apel's continuous innovation in vascular access, offering surgeons improved control and efficiency.
Funding Milestones: Over several funding rounds, the company has significantly increased its capital, facilitating the expansion of its manufacturing capabilities and workforce.
Regulatory Achievements: Q'Apel has achieved FDA clearance for its products, ensuring they meet high regulatory standards for deployment in clinical environments.

Current Operations and Market Position

Q'Apel Medical positions itself as a leader in neurovascular access devices within the U.S. medical technology sector. The company's focus on developing adaptive technologies that meet the clinical demands of surgeons is pivotal to its market growth. Despite facing competitive pressures and recent legal challenges, Q'Apel continues to enhance its market presence through strategic product development and expansion into larger operational facilities.

Conclusion

Q'Apel Medical plays a vital role in the neurovascular medical devices field, driven by innovation and a commitment to improving patient outcomes. Despite recent legal challenges, the company’s forward-thinking approach and growth in funding underscore its potential to expand its influence in international markets. Looking forward, Q'Apel is poised for further advancements in its technology and operational scale, positioning it for enduring success in the healthcare industry.